The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Valeant Pharmaceuticals International Inc

NYSE: VRX
Last

(U.S.) $143.00

Today's change+3.00 +2.14%
Updated December 18 4:02 PM EST. Delayed by at least 15 minutes.
 

Valeant Pharmaceuticals International Inc

NYSE: VRX
Last

(U.S.) $143.00

Today's change+3.00 +2.14%
Updated December 18 4:02 PM EST. Delayed by at least 15 minutes.

Valeant Pharmaceuticals International Inc crosses above 20-day moving average

Valeant Pharmaceuticals International Inc closed up sharply Thursday, rallying (U.S.)$3.00 or 2.14% to (U.S.)$143.00 and crossing above its 20-day moving average. Over the last five days, shares have gained 2.96% and 21.81% year to date. Shares have outperformed the S&P 500 by 13.38% during the last year.

Key company metrics

  • Open(U.S.) $141.90
  • Previous close(U.S.) $140.00
  • High(U.S.) $143.50
  • Low(U.S.) $139.53
  • Bid / Ask(U.S.) $143.05 / (U.S.) $143.08
  • YTD % change+21.81%
  • Volume2,206,221
  • Average volume (10-day)1,670,910
  • Average volume (1-month)1,870,763
  • Average volume (3-month)2,646,303
  • 52-week range(U.S.) $106.00 to (U.S.) $153.10
  • Beta0.89
  • Trailing P/E96.76×
  • P/E 1 year forward16.93×
  • Forward PEG0.63×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $1.48
Updated December 18 4:02 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+6.25%

Based on its net profit margin of 6.25%, Valeant Pharmaceuticals International Inc is less effective than other companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.93%Sector:Industry:
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2014Q2/2014Q1/2014Q4/2013
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014Dec 31, 201312/31/2013
Revenue2,0562,0411,8862,064
Total other revenue--------
Total revenue2,0562,0411,8862,064
Gross profit1,4951,4561,3681,332
Total cost of revenue561586518732
Total operating expense1,3721,6861,6231,876
Selling / general / administrative504516482450
Research & development59676160
Depreciation / amortization393366355204
Interest expense (income), net operating--------
Unusual expense (income)87153250351
Other operating expenses, total-2320-4379
Operating income684355263188
Interest income (expense), net non-operating-258-241-247-263
Gain (loss) on sale of assets--------
Other--------
Income before tax3771215-78
Income after tax276122-20125
Income tax, total100-125-203
Net income275126-23124
Total adjustments to net income--------
Net income before extra. items275126-23124
Minority interest-14-2-1
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items275126-23124
Inc. avail. to common incl. extra. items275126-23124
Diluted net income275126-23124
Dilution adjustment--------
Diluted weighted average shares341341335335
Diluted EPS excluding extraordinary itemsvalue per share0.810.37-0.070.37
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share1.010.670.431.08